====== Braden Manns ======

{{ :public_health_agencies:canada:braden-manns.jpeg?150|}}

Dr. **Braden Manns**, MD, MSc, FRCPC, is Associate Chief Medical Officer for the Strategic Clinical Networks (SCNs) within [[Alberta Health Services]].((Manns, B. (2018). //Introducing Braden Manns.// Alberta Health Services. https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-pfe-newsletter-braden-manns.pdf))

===== Education =====

Manns began his post-secondary education with his Bachelor of Science degree with Honours in Biochemistry from the [[:University of Saskatchewan]], graduating in 1990. 

He received his Doctor of Medicine from the [[:University of Toronto]] in May 1994, graduating with Honours Standing. He completed a General Internal Medicine Residency at the [[:University of Calgary]] in 1997, where he was named a Fellow of the [[:Royal College of Physicians and Surgeons of Canada]], Internal Medicine the following year. He repeated the process with a Nephrology fellowship in 1999. Manns got his Masters in Health Economics at [[:University of York]], England, in October 2000. 

He returned to complete a post-doctoral fellowship in Health Economics at the [[:University of Calgary]] in June 2001.((Manns, B. (2015, July). //BRADEN MANNS, MD, MSc, FRCPC - CV.// https://contacts.ucalgary.ca/info/chs/profiles/1-4840509/braden-j-manns-cv.pdf))
===== Affiliations =====

==== Alberta Health Services ====

Manns is Associate Chief Medical Officer for the Strategic Clinical Networks (SCNs) within [[Alberta Health Services]].((Manns, B. (2018). //Introducing Braden Manns.// Alberta Health Services. https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-pfe-newsletter-braden-manns.pdf)) He is also Co-Chair of the **AHS Scientific Advisory Group** alongside [[Lynora Saxinger]], instructing Alberta's [[:COVID-19]] response.((//2019-nCoV Scientific Advisory Group.// (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf))

=== Suppression of Ivermectin ===

In the latter role, Manns co-authored an article insisting that [[:Ivermectin]] not be used to treat COVID-19. He and his colleagues falsely claimed that "there is no evidence that ivermectin benefits COVID-19 patients, but there are known harms. Ivermectin use has been associated with rash, nausea, vomiting, low blood pressure, abdominal pain, tremors, seizures and severe hepatitis (liver disease) requiring hospitalization." The conclusion they reach is "Vaccination remains our best means of preventing COVID-19. Our vaccines are safe, fully approved and have been studied in high quality trials of tens of thousands of people."((Manns, B., Saxinger, L., & Joffe, M. (2021, October 12). //Alberta Health Services: Ivermectin is a useful drug, but not a treatment for COVID-19.// MSN News; Calgary Herald. https://archive.ph/11Xqr))

The comments left by readers overwhelmingly objected to the authors' statements and accused them of negligence, supporting their criticism with references to the [[:British Ivermectin Recommendation Development]] (BIRD) Group, [[:Pierre Kory]] and [[:Sanjay Gupta]]'s heated exchange with [[:Joe Rogan]] after [[:CNN]] levelled the same propagandistic claims at him.((Heine, D. (2021, October 14). //Joe Rogan Confronts CNN’s Dr. Sanjay Gupta on Network’s COVID Lies.// American Greatness. https://archive.ph/mKmiP)) ((Manns, B., Saxinger, L., & Joffe, M. (2021b, October 12). //Alberta Health Services: Ivermectin is a useful drug, but not a treatment for COVID-19.// Calgary Herald; Postmedia Network Inc. https://calgaryherald.com/opinion/columnists/alberta-health-services-ivermectin-is-a-useful-drug-but-not-a-treatment-for-covid-19))

Members of the public have described Manns as "corrupt". Dr. [[:William Makis]] called for his resignation from the Advisory Group and an investigation into why he and his colleagues blocked Ivermectin.((@MakisMD. (2021, June 15). //We first need a full Investigation of the AHS COVID-19 Scientific Advisory Group lead by NDP/AHS Executive Braden Manns and his associates like  @AntibioticDoc  and  @drslmd.// Twitter. https://archive.ph/lFAhb))
==== Alberta Kidney Disease Network ====

Manns was a member of the [[:Alberta Kidney Disease Network]], which was initially funded by an unrestricted grant from [[pharmaceutical_companies:Amgen]].((//Our Team.// (2017, October 23). Alberta Kidney Disease Network. https://web.archive.org/web/20171023095419/https://www.akdn.info/our-team)) ((Hemmelgarn, B. R., Clement, F., Manns, B. J., Klarenbach, S., James, M. T., Ravani, P., Pannu, N., Ahmed, S. B., MacRae, J., Scott-Douglas, N., Jindal, K., Quinn, R., Culleton, B. F., Wiebe, N., Krause, R., Thorlacius, L., & Tonelli, M. (2009). //Overview of the Alberta Kidney Disease Network.// BMC Nephrology, 10(1). https://doi.org/10.1186/1471-2369-10-30))

==== Alberta SPOR Unit ====

Manns serves on the Steering Committee for the Alberta Strategy for Patient-Oriented Research (SPOR) Unit ([[:AbSPORU]]), which is co-funded by [[:Alberta Innovates]].((//About Us.// Alberta Strategy for Patient Oriented Research SUPPORT Unit (AbSPORU). Retrieved January 8, 2022, from https://archive.ph/3eRHR))

==== BC Renal Agency ====

Manns was a speaker at [[:BC Kidney Days]] on October 24, 2013. The event was hosted by [[:BC Renal Agency]] and [[:BC Transplant]], and accredited by the [[:Canadian Society of Nephrology]]. It was sponsored by [[:pharmaceutical_companies:Amgen]], [[:pharmaceutical_companies:Baxter]], [[:pharmaceutical_companies:Janssen]], [[:pharmaceutical_companies:Alexion]], [[:pharmaceutical_companies:Bellco]], [[:pharmaceutical_companies:Fresenius]], [[:pharmaceutical_companies:Takeda]], [[:pharmaceutical_companies:Gambro]], [[:pharmaceutical_companies:Roche]], [[:pharmaceutical_companies:Abbott]] Nutrition, [[:Ansell]], [[:CardioMed Supplies]], [[:Charles River]], [[:Chief Medical Supplies]], [[:NxStage]], [[:pharmaceutical_companies:Otsuka]], [[:pharmaceutical_companies:Pfizer]], [[:pharmaceutical_companies:Pharmaceutical Partners of Canada]] (PPC), and [[:pharmaceutical_companies:Sanofi]].((//Compassion in Kidney Care: From Patients to Providers.// BC Renal Agency. Retrieved January 8, 2022, from http://www.bcrenal.ca/resource-gallery/Documents/Final_program_design_web.pdf))
==== Can-SOLVE CKD Network ====

Manns served as a co-lead for the Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease ([[:Can-SOLVE CKD Network]]). The initiative is funded by [[:Amgen]], [[:Bayer]], [[:Chinook Therapeutics]], [[:Janssen]], [[:Otsuka]], and others.((//Funding Partners.// Can-SOLVE CKD Network. Retrieved January 8, 2022, from https://cansolveckd.ca/about/funding-partners/))

==== Canadian Expert Drug Advisory Committee ====

Manns served a term as Chair of the [[:Canadian Expert Drug Advisory Committee]], a committee that recommends which new drugs should be paid for within publicly funded drug formularies.

==== Canadian Society of Nephrology ====

Manns served as President of the [[Canadian Society of Nephrology]], funded by [[pharmaceutical_companies:Alexion]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:Eli Lilly]], [[pharmaceutical_companies:Fresenius]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Horizon Therapeutics]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Otsuka]] and [[pharmaceutical_companies:Pfizer]].((//Our Partners.// CSN/SCN. Retrieved January 8, 2022, from https://archive.ph/Omio2)) ((//HE Braden Manns.// O’Brien Institute for Public Health. Retrieved January 8, 2022, from https://obrieniph.ucalgary.ca/research/centres-programs-research-groups-and-units/health-economics/meet-our-team/dr-braden-manns-0)) ((//Our Partners.// Canadian Society of Nephrology. Retrieved October 22, 2022, from https://web.archive.org/web/20221022180917/https://www.csnscn.ca/our-partners/))
==== Kidney Foundation of Canada ====

Manns received the 2017 Medal for Research Excellence from the [[:Kidney Foundation of Canada]], stating "his expertise in applied health economics, health outcomes, pharmaceutical review and priority setting has directly informed health policy and decision-making."((//Dr. Braden Manns.// Kidney Foundation of Canada. Retrieved January 8, 2022, from https://archive.ph/yLyCY)) The Foundation receives significant funding from [[:Otsuka]].((//Virtual Forum 2022.// Kidney Foundation of Canada. Retrieved January 8, 2022, from https://archive.ph/lbb0R))
==== Network of Alberta Health Economists ====

Manns is a member of the [[:Network of Alberta Health Economists]].((//Our Members.// Network of Alberta Health Economists. Retrieved January 8, 2022, from https://noahe.ca/members#))

==== Reformulary ====

Mann serves as a Special Consultant to [[:Reformulary]], a privately-held company that provides drug recommendations.((//About Us.// Reformulary. Retrieved January 8, 2022, from https://archive.ph/KktHK))

==== University of Calgary ====

Manns is a Professor in Health Economics and a Kidney Specialist at the [[University of Calgary]]. In this role, Manns has advocated for increased Federal spending to pay for high cost pharmaceutical drugs in Canada.((Manns, B., & Clement, F. (2017, November 1). //A Different Prescription-Pharmacare isn’t the only solution to high drug costs.// Alberta Views - the Magazine for Engaged Citizens. https://archive.ph/znmjx))

=== Interdisciplinary Chronic Disease Collaboration ===

He also served as co-lead for the University's Interdisciplinary Chronic Disease Collaboration, which was funded by Alberta Innovates (which is partnered with [[:pharmaceutical_companies:Pfizer]]).((Brunner, D. (2018, November 26). //Alberta Government and Pfizer Canada boosts provincial collaborative health innovation partnership with Alberta Innovates.// Alberta Innovates. https://archive.ph/1ppaw))

===== Funding =====

==== Government ====

Manns has received funding from the [[:Canadian Institutes of Health Research Foundation]].((Trachtenberg, A. J., Quinn, A. E., Ma, Z., Klarenbach, S., Hemmelgarn, B., Tonelli, M., Faris, P., Weaver, R., Au, F., Zhang, J., & Manns, B. (2020). //Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis.// CMAJ Open, 8(1), E96–E104. https://doi.org/10.9778/cmajo.20190132))

Manns has also had publications funded by [[:Alberta Innovates]], which is partnered with [[:pharmaceutical_companies:pfizer|Pfizer]].((//Partnerships and Alliances.// (2019, December 3). Pfizer Canada. https://archive.ph/W6hj7)) ((Brunner, D. (2018, November 26). //Alberta Government and Pfizer Canada boosts provincial collaborative health innovation partnership with Alberta Innovates.// Alberta Innovates. https://archive.ph/1ppaw)) 

One such study is "COVID-19 Vaccine-Related Attitudes and Beliefs in Canada: National Cross-sectional Survey and Cluster Analysis", which concluded "Messaging related to preventing COVID among friends and family, highlighting the benefits, emphasizing safety and efficacy of COVID-19 vaccination, and ensuring that health care workers are knowledgeable and supported in their vaccination counselling may be effective for vaccine-hesitant populations."((Benham, J. L., Atabati, O., Oxoby, R. J., Mourali, M., Shaffer, B., Sheikh, H., Boucher, J.-C., Constantinescu, C., Parsons Leigh, J., Ivers, N. M., Ratzan, S. C., Fullerton, M. M., Tang, T., Manns, B. J., Marshall, D. A., Hu, J., & Lang, R. (2021). //COVID-19 Vaccine–Related Attitudes and Beliefs in Canada: National Cross-sectional Survey and Cluster Analysis.// JMIR Public Health and Surveillance, 7(12), e30424. https://doi.org/10.2196/30424))

Another is "Characterization of non-adopters of COVID-19 non-pharmaceutical interventions through a national cross-sectional survey to assess attitudes and behaviours".((Lang, R., Atabati, O., Oxoby, R. J., Mourali, M., Shaffer, B., Sheikh, H., Fullerton, M. M., Tang, T., Leigh, J. P., Manns, B. J., Marshall, D. A., Ivers, N. M., Ratzan, S. C., Hu, J., & Benham, J. L. (2021). //Characterization of non-adopters of COVID-19 non-pharmaceutical interventions through a national cross-sectional survey to assess attitudes and behaviours.// Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-01279-2))

Yet another is "Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging".((Lang, R., Benham, J. L., Atabati, O., Hollis, A., Tombe, T., Shaffer, B., Burns, K. K., MacKean, G., Léveillé, T., McCormack, B., Sheikh, H., Fullerton, M. M., Tang, T., Boucher, J.-C., Constantinescu, C., Mourali, M., Manns, B. J., Marshall, D. A., Hu, J., & Oxoby, R. J. (2021). //Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging.// BMC Public Health, 21(1). https://doi.org/10.1186/s12889-021-10790-0))
==== Pharmaceutical Companies ====

Manns has received funding via an unrestricted grant from [[pharmaceutical_companies:Baxter]].((Trachtenberg, A. J., Quinn, A. E., Ma, Z., Klarenbach, S., Hemmelgarn, B., Tonelli, M., Faris, P., Weaver, R., Au, F., Zhang, J., & Manns, B. (2020). //Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis.// CMAJ Open, 8(1), E96–E104. https://doi.org/10.9778/cmajo.20190132))

===== Media Appearances =====

==== Podcasts ====

  * [[https://www.campfire.wiki/lib/exe/fetch.php?media=public_health_agencies:canada:scn_podcast_-_december_2021.mp3|SCN Podcast - December 2021]]((AHS Communications. (2021, December). //SCN Podcast - December 2021.// SoundCloud. https://soundcloud.com/ahs-communications/scn-podcast-december-2021))

===== External links =====

  * [[https://www.whiteroseintelligence.com/braden-manns/|White Rose Wiki]]